Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 108

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 108
---
 the employer specific to that employer’s business and not just regarding the professional development of the employee. If it is not able to enforce non-compete covenants, it may be faced with added competition.

<div align='center'>72

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Some of the statements made under “Our Business and “Use of Proceeds” and elsewhere in this prospectus, including in our 2023 Annual Report, or incorporated by reference herein constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” “intends” or “continue,” or the negative of these terms or other comparable terminology.

These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our product candidates, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.

Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:

| ● | the regulatory                                                                               
 pathways that we may elect to utilize in seeking European Medicines Agency, or EMA, the U.S. 
 Food and Drug Administration, or FDA, and other regulatory approvals;                        |

| ● | that                                                                                     
 our financial position raises substantial doubt about our ability to continue as a going 
 concern;                                                                                 |

| ● | our                                                                                            
 ability to maintain listing and effectively comply with the listing requirements of The Nasdaq 
 Stock Market LLC, or Nasdaq;                                                                   |

| ● | the                                                                                           
 completion and timing of the transaction contemplated by our Merger Agreement with Kadimastem 
 are uncertain, and the risk that the transaction may not close as expected or at all;         |

| ● | our                                                                                                    
 ability to drive revenue